The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| UTHR | +10.71% | +223.89% | +26.5% | +7,349% |
| S&P | +13.96% | +91.24% | +13.85% | +410% |
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Here are the five best biotech ETFs to invest in right now.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $799.50M | 6.8% |
| Gross Profit | $698.60M | 4.9% |
| Gross Margin | 87.38% | -1.5% |
| Market Cap | $18.96B | 18.9% |
| Market Cap / Employee | $14.53M | 0.0% |
| Employees | 1.3K | 11.7% |
| Net Income | $338.70M | 9.6% |
| EBITDA | $411.20M | 13.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.14B | -26.9% |
| Accounts Receivable | $297.70M | -12.9% |
| Inventory | 176.5 | 20.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 17.57% | 1.9% |
| Return On Invested Capital | 13.90% | 4.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $351.60M | 18.0% |
| Operating Free Cash Flow | $562.10M | 50.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 14.34 | 12.30 | 11.22 | 15.89 | 0.95% |
| Price to Book | 2.58 | 2.14 | 1.90 | 2.64 | 0.83% |
| Price to Sales | 5.97 | 5.00 | 4.51 | 6.34 | 0.72% |
| Price to Tangible Book Value | 2.63 | 2.18 | 1.93 | 2.68 | 0.54% |
| Price to Free Cash Flow TTM | 15.94 | 13.31 | 12.99 | 17.67 | -8.48% |
| Enterprise Value to EBITDA | 37.67 | 29.46 | 26.59 | 41.49 | 4.23% |
| Free Cash Flow Yield | 6.3% | 7.5% | 7.7% | 5.7% | 9.27% |
| Return on Equity | 19.2% | 19.9% | 19.3% | 20.0% | 6.55% |
| Total Debt | $300.00M | $200.00M | $0.00M | $0.00M | - |
No podcast episodes available.
UTHR earnings call for the period ending September 30, 2021.
UTHR earnings call for the period ending June 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
